Placing the P Value into Perspective: Does Paclitaxel Add Value to Gemcitabine and Cisplatin in Advanced Urothelial Cancers?

This JCO Podcast provides observations and commentary on the JCO article, "Randomized Phase III study comparing Paclitaxel Cisplatin Gemcitabine and Gemcitabine Cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC 30987 Intergroup Study" by Joaquim Bellmunt et al. It provides my perspective that considers both statistical metrics and clinical outcomes in decision making for difficult to treat diseases.